Table 2. Sensitivity and Specificity of PI-RADS 2.0 and PI-RADS 2.1 scores for both readers in the detection of prostate cancer and clinically significant prostate cancer (Gleason score ≥ 3+4).
A PI-RADS score ≥ 4 was deemed to indicate positivity for cancer.
| Sensitivity (95% CI) | Specificity (95% CI) | ||||
|---|---|---|---|---|---|
| PI-RADS 4+5 | Reader 1 | Cancer | PI-RADS 2.0 | 0.791 (0.718–0.848) | 0.901 (0.817–0.949) |
| PI-RADS 2.1 | 0.791 (0.718–0.848) | 0.901 (0.817–0.949) | |||
| Clinically significant cancer | PI-RADS 2.0 | 0.813 (0.729–0.876) | 0.861 (0.788–0.911) | ||
| PI-RADS 2.1 | 0.813 (0.729–0.876) | 0.861 (0.788–0.911) | |||
| Reader 2 | Cancer | PI-RADS 2.0 | 0.728 (0.623–0.813) | 0.730 (0.653–0.795) | |
| PI-RADS 2.1 | 0.728 (0.623–0.813) | 0.730 (0.653–0.795) | |||
| Clinically significant cancer | PI-RADS 2.0 | 0.654 (0.560–0.738) | 0.762 (0.679–0.829) | ||
| PI-RADS 2.1 | 0.654 (0.560–0.738) | 0.762 (0.679–0.829) | |||
| PI-RADS 3+4+5 | Reader 1 | Cancer | PI-RADS 2.0 | 0.878 (0.816–0.922) | 0.753 (0.649–0.834) |
| PI-RADS 2.1 | 0.878 (0.816–0.922) | 0.753 (0.649–0.834) | |||
| Clinically significant cancer | PI-RADS 2.0 | 0.926 (0.866–0.961) | 0.654 (0.560–0.738) | ||
| PI-RADS 2.1 | 0.926 (0.866–0.961) | 0.654 (0.560–0.738) | |||
| Reader 2 | Cancer | PI-RADS 2.0 | 0.872 (0.808–0.916) | 0.457 (0.353–0.565) | |
| PI-RADS 2.1 | 0.878 (0.816–0.922) | 0.432 (0.330–0.541) | |||
| Clinically significant cancer | PI-RADS 2.0 | 0.885 (0.817–0.930) | 0.393 (0.305–0.487) | ||
| PI-RADS 2.1 | 0.893 (0.826–0.937) | 0.374 (0.288–0.468) |